Indeed, in melanoma, recent studies indicate significant enhancement of activity of PD-1 blockade when combined with CTLA-4 blockade, an effect that was primarily seen in patients with PD-L1-non-expressing tumours7. Here, CTLA4 is linked to melanoma.